Tillkännagivande • Apr 02
3SBio Inc. Resolves to Declare Final Dividend for the Year Ended 31 December 2025, Payable on or Around 4 August 2026 The Board of 3SBio Inc. resolved to declare a final dividend of 25 HK cents per share for the year ended 31 December 2025 (2024: 25 HK cents) to those shareholders whose names appeared on the register of members of the Company on 27 July 2026, which will be paid out of the Company's share premium account. Subject to the approval of shareholders of the Company at the forthcoming annual general meeting ("AGM"), the final dividend will be paid in cash on or around 4 August 2026. Tillkännagivande • Mar 31
3SBio Inc., Annual General Meeting, Jun 25, 2026 3SBio Inc., Annual General Meeting, Jun 25, 2026. Tillkännagivande • Mar 17
3SBio Inc. to Report Fiscal Year 2025 Results on Mar 30, 2026 3SBio Inc. announced that they will report fiscal year 2025 results on Mar 30, 2026 Tillkännagivande • Dec 10
3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. 3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 105,169,500
Price\Range: HKD 29.62
Transaction Features: Subsequent Direct Listing Tillkännagivande • Dec 03
3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion. 3SBio Inc. has filed a Follow-on Equity Offering in the amount of HKD 3.115121 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 105,169,500
Price\Range: HKD 29.62
Transaction Features: Subsequent Direct Listing Tillkännagivande • Aug 19
3SBio Inc. to Report First Half, 2025 Results on Aug 29, 2025 3SBio Inc. announced that they will report first half, 2025 results on Aug 29, 2025 Tillkännagivande • Aug 01
3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million. 3SBio Inc. has completed a Follow-on Equity Offering in the amount of HKD 784.962284 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 31,142,500
Price\Range: HKD 25.2055 Tillkännagivande • Apr 17
3SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration 3SBio Inc. on a voluntary basis. On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ("BTD") by China's National Medical Products Administration (" NMPA"). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ("NSCLC"). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform. It is currently undergoing multiple clinical studies in China, including a phase III clinical study for the first-line treatment ofPD-1 positive locally advanced and metastatic NSCLC already approved by the Center for Drug Evaluation ("CDE") of the NMPA. Additionally, 707 Injection is undergoing several phase II studies in China, including combination therapy with chemotherapy for the first-line treatment of advanced NSCLC, metastatic colorectal cancer, and advanced gynecological tumours. It has also received approval from the U.S. Food and Drug Administration in relation to its Investigational New Drug application. The CDE will provide policy support for drugs that have been granted BTDs, prioritize resource allocation for communication, enhance guidance, and accelerate drug development. When submitting a New Drug Application, if it is evaluated to meet the relevant conditions, the qualification for priority review and approval may be granted, expediting the market launch process. There is no assurance that the product will eventually be commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. Tillkännagivande • Mar 25
3SBio Inc., Annual General Meeting, Jun 25, 2025 3SBio Inc., Annual General Meeting, Jun 25, 2025. Tillkännagivande • Mar 07
3SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 2025 3SBio Inc. announced that they will report fiscal year 2024 results on Mar 25, 2025 Tillkännagivande • Aug 12
3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024 3SBio Inc. announced that they will report first half, 2024 results on Aug 22, 2024 Tillkännagivande • Apr 23
3Sbio Inc. Announces Management Changes 3SBio Inc. announced that in accordance with the articles of association of the Company, Dr. ZHANG Dan ("Dr. Zhang"), an independent non-executive Director, will retire by rotation at the forthcoming annual general meeting (the "AGM") of the Company which is to be held on 25 June 2024. He will not seek for re-election due to his other business commitments. His retirement will take effect upon the conclusion of the AGM and, accordingly, he will cease to be a member of the remuneration committee of the Board ("Remuneration Committee") at the conclusion of the AGM. The Board further announces that Mr. NG, Joo Yeow Gerry, an independent non-executive Director, has been appointed by the Board as a member of the Remuneration Committee with effect immediately after the conclusion of the 2023 AGM to be held on 25 June 2024. Tillkännagivande • Mar 06
3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024 3SBio Inc. announced that they will report fiscal year 2023 results on Mar 20, 2024 Tillkännagivande • Jan 09
Mandi Foam of 3SBio Inc. Approves for Market Launch 3SBio Inc. announced that the application for market launch of Mandi (5% minoxidil) Foam as an over-the-counter drug for the treatment of androgenetic alopecia and alopecia areata by its subsidiary, Zhejiang Wansheng Pharmaceutical Co. Ltd., to the National Medical Products Administration (NMPA) of the PRC has been approved. Mandi Foam is the new-generation anti-hair loss and hair growth product of 3SBio group based on Minoxidil Tincture (trade name: Mandi), which is also the first domestic minoxidil foam approved for market launch. Previously, the result of such product in "a multi-centered, double-blind, randomized controlled clinical trial to assess the efficacy of Mandi Foam and ROGAINE® (5% Minoxidil Foam) on patients with androgenetic alopecia in terms of their equivalence, safety and tolerability" reached the preset statistical end point, indicating that the efficacy of Mandi Foam is equivalent to that of the controlled medicine, ROGAINE®. Minoxidil is currently a first-line topical drug for the clinical treatment of androgenetic alopecia. Mandi Foam has better transdermal speed and scalp accumulation rate, with milder scalp tolerance, rendering it a better choice for alopecia users. Tillkännagivande • Aug 12
3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023 3SBio Inc. announced that they will report first half, 2023 results on Aug 24, 2023 Tillkännagivande • Jul 29
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer 3SBio Inc. announced that with effect from 3 July 2023, Mr. HE Xiang ("Mr. He") has been appointed as the new chief financial officer of the Company. Mr. He will be responsible for investment and finance activities, as well as investor relations management of the Group. The biographical details of Mr. He are as follows: Mr. He graduated from the Guanghua School of Management of Peking University with a master degree in Finance. He has served Citigroup and J.P. Morgan investment banking in Beijing, Shanghai, New York and Hong Kong, and has 15 years of experience in investments, financings, and capital markets. He is a registered sponsor principal with the Securities and Futures Commission of Hong Kong. During his tenure in J.P. Morgan, he held different roles including Head of Corporated Finance and Head of Financial Institutions for China, and gained extensive experiences in equity private placements, initial public offerings, follow-on offerings and mergers and acquisitions for various corporates across pharmaceutical, healthcare as well as other sectors. Tillkännagivande • Jul 06
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market 3SBio Inc. announced that the new drug application of narfuraphine hydrochloride orally disintegrating tablets submitted to the National Medical Products Administration of China (NMPA) being approved for launch in the market. This is a voluntary announcement made by the Company. There is no assurance that the Company will eventually successfully launch and/or commercialize the product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. 3SBio Inc. announced that The new drug application of narfurphine hydrochloride orally disintegrated tablets (Li Mei Zhi®?, trade name in Japan; " remitsuchiODDING 2.5ug") submitted To the National Medical Products Administration ofChina (NMPA) has been approved (Guoyaozhunzi No. HJ20230091) for the improvement of pruritus in hemodialysis patients (only in cases where the efficacy of existing treatments is not satisfactory). This is the first and only selective k (kappa)-opioid receptor agonist approved by the NMPA to treat hemodialysis patients with refractory pruritus. In addition, the clinical trial application for this product to improve pruritus in patients with chronic liver disease (only in cases where the effectiveness of existing treatments is not satisfactory) was approved in May this year (Notice No.: 2023LP00912). Hemodialysis patients are often accompanied by various complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperthyroidism, and pruritus. Currently, there is still no recognized effective treatment for pruritus in most of the patients, which causes great mental and physical pain to the patients and significantly reduces their quality of life. Tillkännagivande • Jan 04
3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director 3SBio Inc. provided supplemental information on the resignation of Mr. Tang Ke. Mr. Tang tendered his resignation as a non-executive Director as he needs to devote more time to his personal commitments and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders or the Stock Exchange. 
